drugset / Trial / NCT06487429
Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
Phase 2
Recruiting
28 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RemeGen Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, open label, phase II clinical study intended to include patients with locally advanced gastric adenocarcinoma who have not undergone any treatment and are eligible for surgery. The study aims to evaluate the efficacy and safety of the short course sequential radiotherapy regimen of Disitamab Vedotin combined with S-1 and Sintilimab in neoadjuvant therapy for HER2 expressing locally advanced gastric cancer.
Timeline
- Start
- 2024-05-08
- Primary completion
- 2026-05-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |